only if there were elevations of alkaline phosphatase, aspartate aminotransferase, or bilirubin levels. Patients had to have recovered from surgery rapidly and been breathing on their own at the time of randomization.
Experimental Design
Patients were stratified according to treatment center, stage (II or III), weight loss (>-10% vs <10%), and age (<60 vs -60 years), then assigned within 21 days of surgery to either the treatment or control arm by permuted block randomization within strata after eligibility had been verified.
Radiation Therapy
Patients were scheduled to receive 50 Gy measured in the central axis at the midplane delivered by megavoltage equipment using a combination of parallel opposed anterior and posterior and oblique fields or any combination of these under the direction of the radiation oncologist of record. Fields encompassed the suprasternal notch superiorly, extended 5 cm below the carina, and included the bronchial stump and ipsilateral hilum and vascular shadows of the mediastinum bilaterally. The dose to the spinal cord was limited to 45 Gy, measured 2 to 3 cm below the cephalad margin.
Follow-up
Follow-up evaluation was performed 6 weeks after surgery, quarterly for 2 years, and then semiannually thereafter. This included history and physical examination, Karnofsky Performance Status, complete blood cell count, alkaline phosphatase, aspartate aminotransferase, bilirubin, and chest radiograph. Disease-free interval was determined by the number of days from randomization to the detection of first confirmed recurrence or metastasis. Survival was calculated as the number of days from randomization to death.
Statistical Analysis
The 
RESULTS

Stratification
Stratification was successful, with no significant imbalance of baseline covariates noted between the two groups ( Table 1) . 
Toxicity
As expected, there was increased esophagitis (24% overall, 3% severe according to Eastern Cooperative Group criteria'2), other gastrointestinal symptoms (20%), and dermatologic (11%) and neurologic toxic reactions (10%) in the treatment group. Pulmonary toxic reactions, however, were not significantly different between the groups (16% in the radiotherapy group and 9% in the control group). The toxic reactions were life threatening in three patients; one in the control group and two in the radiotherapy group.
Treatment Compliance
Among the 102 patients in the radiation therapy arm, Table 2 because of the large number of systemic recurrences.
Analysis of Survival
The addition of radiotherapy did not significantly affect survival (Table 2 and Fig 2) . Twenty-one patients died without recurrence: 14 Analysis of the recurrence rate and survival among the 92 eligible patients who received radiotherapy (the "pure" radiotherapy group) and the 105 eligible control patients who did not receive radiotherapy initially (the "pure" control group), although not fully protected by randomization and possibly subject to selection bias, showed no difference between groups. Analysis of the recurrence rates and survival according to nodal status demonstrated a significant reduction in overall recurrence rates only in patients with N2 disease (p=0.031) ( concern in interpreting these data is that the selection process for treatment is not stated, leading to the possibility that the radiotherapy group could be either healthier or sicker than the nontreated group. Kirsh and Sloan'4 intended to treat all patients with radiotherapy, but 15% of the patients did not receive it. The authors state that these patients were not different than those who received treatment, though none of them survived 5 years. Another concern is that the surgical staging in the series by Choi The 5-year survival in LCSG 773 was 38%, which is slightly higher than the rates of survival for the studies for epidermoid carcinoma in Table 5 . This likely reflects differences in eligibility criteria and pretherapy diagnostic and surgical evaluation.
A number of criticisms of LCSG 773 have been expressed. It has been suggested that since only 76% of the patients received within 5% of the intended dose, the results might have been better if compliance had been better. 17-20 Additionally, concern has been expressed about the inclusion of 12 control patients who received radiotherapy after having local recurrence without distant metastases.21
However, subset analysis of the survival of those patients who received within 5% of the protocol dose compared with those control patients who did not receive initial or delayed radiotherapy revealed no significant benefit in survival. 13 Because of the increase in noncancer deaths associated with respiratory and cardiac failure (11 in the radiotherapy group and 5 in the control group), it has been suggested that inadequate cardiorespiratory screening was the cause of the lack of apparent benefit of the radiotherapy.20 The slight excess of deaths in the radiotherapy group without cancer, however, was not statistically significant.
Limited pretreatment evaluation with bone and liver scans only in cases of elevated liver or bone enzyme levels has also been mentioned as a possible confounding factor,20'22 with the possibility of a larger number of patients in the radiotherapy group with occult metastatic disease than in the control group. There is, however, no evidence that there would be a difference in survival between the groups in patients with normal scans.13
The question of adequacy of the scheduled dose has been raised, with the suggestion that higher doses would be indicated in the postoperative setting.20 However, no evidence is available to indicate that higher doses would provide more substantial local control in this group of patients in whom complete resection has been performed. In addition, the desired effect of the radiotherapy, which was loco-regional control, was achieved with the scheduled dose.
One criticism has been the inclusion of patients with NO disease, variously quoted as 7%17 and 11%19 of the entire group, who would not have had radiotherapy recommended. However, only 4% of the patients in the study (9 of 210: 7 in the radiotherapy and 2 in the control group) had normal lymph nodes. The recurrence rate was higher in the control patients with NO disease ( 17 However, results from LCSG 772,23 which consisted of patients with similarly staged disease as LCSG 773 but with adenocarcinoma and large cell histologic features, indicate that the incidence of local-only as the first site of recurrence was significantly less (17% of first recurrences) than in pa-tients with epidermoid carcinoma (41% of first recurrences), and therefore preventing local disease as the first site of metastasis would likely have less benefit in patients with adenocarcinoma compared with patients with epidermoid carcinoma.
Postoperative irradiation is intended to reduce local or regional recurrence and, hopefully, subsequently reduce systemic relapse. The data generated by LCSG 773 indicated that postoperative irradiation significantly reduced local recurrence in patients with epidermoid carcinoma, but that this benefit did not result in increased survival in the population studied because of the large percentage of patients who had recurrences outside the loco-regional area. Because lung cancer metastasizes early, local methods of treatment in patients who have regional metastases are unlikely to be sufficient. 24 The need for effective systemic therapy is clear.
